Skip to main content

Advertisement

Table 1 Comparison of global outcome measures, comparing basal (pre) and after one year (post) on a GFD: Change is calculated as the percentage improvement in scores

From: Clinical impact of a gluten-free diet on health-related quality of life in seven fibromyalgia syndrome patients with associated celiac disease

  Pre-GFD Post-GFD Change (%) P
TPs (scale 0–18) 16.3 (2.4) 8.0 (1.6) 8.3 (51) < 0.001
FIQ (scale 0–80) 74.3 (2.9) 36.6 (4.0) 37.7 (51) < 0.001
HAQ (scale 0–3) 1.7 (0.6) 0.7 (0.3) 1.0 (52) < 0.001
VAS digestive (scale 0–100) 47.8 (2.4) 19.1 (0.8) 28.7 (60) < 0.001
VAS pain (scale 0–10) 8.0 (0.5) 3.9 (1.0) 4.1 (52) < 0.001
VAS fatigue (scale 0–10) 7.9 (0.3) 3.9 (0.8) 4.0 (51) < 0.001
SF36-PCS (scale 0–100) 27.4 (3.6) 40.4 (5.1) +13.0 (48) < 0.001
SF36-MCS (scale 0–100) 17.4 (2.9) 27.8 (3.3) +10.4 (60) < 0.001
Prescribed drugs (N) 6.6 (1.5) 3.3 (0.5) 3.6 (55) < 0.001
tTG2 (U/ml) 60.4 (52.2) 0.7 (0.2) 59.7 (98) < 0.05
  1. Data are expressed as mean and standard deviation. TPs Tender Points. FIQ Fibromyalgia Impact Questionnaire. HAQ Health Assessment Questionnaire. VAS Visual Analogue Scale. SF-36 Short Form Health Survey; PCS Physical Component Summary; MCS Mental Component Summary. N number. tTG-2 Tissue Trans-Glutaminase-2. P < 0.05, significant; P < 0.001, highly significant.